I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

NCT ID: NCT00802347

Last Updated: 2014-09-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 374 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2014-05-31

Brief Summary

The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation. In this Phase I /II study, patients who are undergoing renal transplantation with organs from DCD donors, ECD donors or SCD donors with ≥ 24 hours of cold ischemia time who meet study entry criteria will be studied to evaluate the safety and pharmacokinetic profile of I5NP (Part A) and clinical activity of I5NP administration (Part B). Data from this study will be used to identify doses of I5NP to be used in follow-on efficacy studies.

Part A will be a randomized, dose escalation study to determine the highest or maximum tolerated dose (MTD). Part A will enroll 40 patients at approximately 20 sites; patients will be randomized to receive either I5NP or placebo in a ratio of 8:2 in each cohort (cohorts 1-4).

Part B will utilize the dose identified in Part A to further evaluate, in a double-blind manner, the safety, and clinical activity of I5NP. In Part B, up to 326 patients will participate at approximately 60 sites; up to 163 patients will be randomized to receive I5NP and up to 163 patients randomized to receive placebo.

Detailed Description

Although the etiology of DGF is not fully understood and may be multifactorial, the pathophysiology appears to be primarily related to ischemia-reperfusion (IR) injury resulting from organ preservation between the times of harvesting from the donor and reperfusion following vascular reanastomosis in the recipient.

I5NP is a small interfering RNA (siRNA) that is being developed for the prophylaxis of delayed graft function (DGF) in patients receiving renal transplants.

Conditions

Delayed Graft Function; Other Complication of Kidney Transplant

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

I5NP

Group Type: EXPERIMENTAL

I5NP

Intervention Type: DRUG

Single IV injection of I5NP

Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg

Part B: 10.0 mg/kg

Saline

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: DRUG

Single IV injection of saline

Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg

Part B: 10.0 mg/kg

Interventions

I5NP

Single IV injection of I5NP

Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg

Part B: 10.0 mg/kg

Intervention Type: DRUG

Saline

Single IV injection of saline

Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg

Part B: 10.0 mg/kg

Intervention Type: DRUG

Other Intervention Names

QPI-1002

Eligibility Criteria

Inclusion Criteria

1. Patient is at least 18 years of age.

2. Patient has given informed consent.

3. Patient is willing to practice birth control. Female patients must be: (1) post-menopausal (2) surgically sterile, or (3) using an effective means of contraception (per the site-specific guidelines or using 2 methods of birth control concurrently, whichever is more stringent) which will be continued until the Study Day 90 visit with a negative pregnancy test within 48 hours prior to administration of study drug. Male patients with female partners of child bearing potential must agree to use an effective means of contraception (per the site-specific guidelines or using 2 methods of birth control concurrently, whichever is more stringent) which will be continued until the Study Day 90 visit. Note: For the purpose of this study, post menopausal is defined as the absence of menses consistent with ESRD. A woman is considered to be surgically sterilized if she has had a bilateral tubal ligation for at least 6 months prior to administration of study drug, bilateral oophorectomy, or complete hysterectomy.

4. Women of childbearing potential test negative for pregnancy (either urine or serum) within 48 hours prior to transplant.

5. Patient is up-to-date on cancer screening according to site-specific guidelines and the past medical history is negative for biopsy-confirmed malignancy within 5 years of randomization, with the exception of adequately treated basal cell or squamous cell carcinoma in situ.

6. Patient is scheduled to receive kidney transplant from a deceased donor meeting the following criteria:

Part A:

• receipt of an extended criteria donor (ECD) kidney, or
• receipt of a kidney donated after cardiac death (DCD), or
• receipt of a standard criteria donor (SCD) with cold ischemia time (CIT) ≥ 24 hours.

Part B:

• receipt of an ECD kidney that has been preserved by cold storage (ECD/CS) for the entire period of cold ischemia time (CIT), regardless of duration
• receipt of an ECD kidney that has been preserved by machine perfusion (ECD/MP) for any interval of time during the period of cold ischemia, where total CIT has been at least 26 hours
• receipt of an SCD kidney that has been preserved by cold storage (SCD/CS) where total CIT has been at least 26 hours
• receipt of an SCD kidney that has been preserved by machine perfusion (SCD/MP) for any interval of time during the period of cold ischemia, where total CIT has been at least 26 hours.

7. Patient is dialysis dependent at the time of transplant as documented by: a) the requirement for at least 2 dialysis sessions/week during the 56 days prior to transplant, or b) the planned removal of any remaining native kidney at the time of transplant, or c) the opinion of the investigator that the patient has no remaining native renal function (Part A only), or d) the investigator has provided documentation to the Medical Monitor that the patient has no remaining native renal function (e.g., documentation that the patient is anuric, with urine output <50 mL/day) (Part B only).

Exclusion Criteria

1. Patient has participated in an investigational drug study in the last 30 days.

2. Patient has known allergy or has participated in prior study with siRNA.

3. Patient is HCV-positive

4. Patient is HIV-positive

5. Patient is scheduled to undergo multiorgan transplantation.

6. Patient has a planned transplant of kidneys that are implanted en bloc (dual kidney transplant).

7. Patient has planned transplant of kidneys from donors < 6 years of age.

8. Patient has planned transplant of dual kidneys (from the same donor) transplanted not en bloc (as in the case of dual ECD donor kidneys).

9. Patient is scheduled for transplantation of a kidney from a donor who is known to have received an investigational therapy (under another IND) for ischemic/reperfusion injury immediately prior to organ recovery.

10. Patient is scheduled to receive a living donor kidney.

11. Patient is scheduled to receive an ABO-incompatible donor kidney.

12. Patient is scheduled to receive an organ from a donor that meets both DCD and ECD criteria.

13. Patient is scheduled to receive an organ from a donor that meets DCD criteria (exclusion applicable to Part B only).

14. Patient has history or presence of a medical condition or disease that in the investigator's assessment would place the patient at an unacceptable risk for study participation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Quark Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shai Erlich, Ph.D.

Role: STUDY_DIRECTOR

Quark Pharmaceuticals

Locations

University of Alabama Birmingham

Birmingham, Alabama, United States

Loma Linda University Medical Center

Loma Linda, California, United States

University of Southern California

Los Angeles, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Transplant Research Institute (TRI; formerly NIT)

Los Angeles, California, United States

UCLA Medical Center

Los Angeles, California, United States

UC Davis Medical Center

Sacramento, California, United States

California Pacific Medical Center

San Francisco, California, United States

UCSF Medical Center

San Francisco, California, United States

University of Colorado Health Science Center

Aurora, Colorado, United States

Washington Hospital Center

Washington D.C., District of Columbia, United States

University of Florida

Gainesville, Florida, United States

University of Miami

Miami, Florida, United States

Lifelink Healthcare Institute

Tampa, Florida, United States

Piedmont Hospital

Atlanta, Georgia, United States

Emory University

Atlanta, Georgia, United States

Rush University

Chicago, Illinois, United States

University of Illinois Chicago

Chicago, Illinois, United States

University of Maryland

Baltimore, Maryland, United States

Johns Hopkins University

Baltimore, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Saint Barnabas Medical Center

Livingston, New Jersey, United States

Columbia University

New York, New York, United States

Cornell University

New York, New York, United States

Duke University

Durham, North Carolina, United States

Wake Forest University Medical Center

Winston-Salem, North Carolina, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Baylor University Medical Center

Dallas, Texas, United States

Baylor All Saints Medical Center

Fort Worth, Texas, United States

The Methodist Hospital

Houston, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

Virginia Commonwealth University (MCV)

Richmond, Virginia, United States

St. Paul's Hospital, Univeristy of BC

Vancouver, British Columbia, Canada

UBC - Division of Nephrology

Vancouver, British Columbia, Canada

QE II Capital District Health Authority, Halifax

Halifax, Nova Scotia, Canada

MUHC Royal Victoria Hospital

Montreal, Quebec, Canada

Hôpital Pasteur

Nice, , France

Hôpital Necker

Paris, , France

CHU Rangueil

Toulouse, , France

Charité - Universitätsmedizin Berlin

Berlin, , Germany

Charité, Campus Virchow-Klinikum

Berlin, , Germany

Kliniken der Stadt Köln gGmbH

Cologne, , Germany

Universitätklinikum Hamburg-Eppendorf

Hamburg, , Germany

Universitätsklinikum Heidelberg

Heidelberg, , Germany

Universitätsmedizin Mannheim

Mannheim, , Germany

Universitätsklinikum Tübingen

Tübingen, , Germany

Hospital de bellvitge

Barcelona, , Spain

Hospital del mar

Barcelona, , Spain

Hospital Vall Hebron

Barcelona, , Spain

Countries

United States; Canada; France; Germany; Spain

Other Identifiers

QRK.006

Identifier Type: -

Identifier Source: org_study_id